{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:18:23Z","timestamp":1761196703563},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T00:00:00Z","timestamp":1146182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Springer Semin Immun"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s00281-006-0013-8","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T10:30:09Z","timestamp":1146220209000},"page":"443-456","source":"Crossref","is-referenced-by-count":16,"title":["Biological therapies directed against cells in autoimmune disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Paul","family":"Hasler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,28]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344:1140\u20131144","journal-title":"N Engl J Med"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058\u20131066","journal-title":"N Engl J Med"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0950-3579(05)80186-4","volume":"6","author":"JM Dayer","year":"1992","unstructured":"Dayer JM, Fenner H (1992) The role of cytokines and their inhibitors in arthritis. Baillieres Clin Rheumatol 6:485\u2013516","journal-title":"Baillieres Clin Rheumatol"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0049-0172(96)80034-5","volume":"25","author":"RW McMurray","year":"1996","unstructured":"McMurray RW (1996) Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 25:215\u2013233","journal-title":"Semin Arthritis Rheum"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/ar1718","volume":"7","author":"J Leipe","year":"2005","unstructured":"Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H (2005) Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 7:93\u201399","journal-title":"Arthritis Res Ther"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11926-003-0003-y","volume":"5","author":"SR Bennett","year":"2003","unstructured":"Bennett SR, Falta MT, Bill J, Kotzin BL (2003) Antigen-specific T cells in rheumatoid arthritis. Curr Rheumatol Rep 5:255\u2013263","journal-title":"Curr Rheumatol Rep"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/ard.2003.013060","volume":"63","author":"K Nissler","year":"2004","unstructured":"Nissler K, Pohlers D, Huckel M, Simon J, Brauer R, Kinne RW (2004) Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation. Ann Rheum Dis 63:1470\u20131477","journal-title":"Ann Rheum Dis"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.4049\/jimmunol.165.12.7240","volume":"165","author":"RO Williams","year":"2000","unstructured":"Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN (2000) Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha\/anti-CD4 therapy. J Immunol 165:7240\u20137245","journal-title":"J Immunol"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.4049\/jimmunol.157.6.2685","volume":"157","author":"CQ Chu","year":"1996","unstructured":"Chu CQ, Londei M (1996) Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J Immunol 157:2685\u20132689","journal-title":"J Immunol"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/ar404","volume":"4","author":"D Pohlers","year":"2002","unstructured":"Pohlers D, Schmidt-Weber CB, Franch A, Kuhlmann J, Brauer R, Emmrich F, Kinne RW (2002) Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cells. Arthritis Res 4:184\u2013189","journal-title":"Arthritis Res"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1365-2249.2001.01592.x","volume":"125","author":"C Pelegri","year":"2001","unstructured":"Pelegri C, Castell M, Serra M, Rabanal M, Rodriguez-Palmero M, Castellote C, Franch A (2001) Prevention of adjuvant arthritis by the W3\/25 anti-CD4 monoclonal antibody is associated with a decrease of blood CD4(+)CD45RC(high) T cells. Clin Exp Immunol 125:470\u2013477","journal-title":"Clin Exp Immunol"},{"key":"13_CR12","first-page":"325","volume":"18","author":"D Wendling","year":"1991","unstructured":"Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B (1991) Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 18:325\u2013327","journal-title":"J Rheumatol"},{"key":"13_CR13","first-page":"1457","volume":"25","author":"D Wendling","year":"1998","unstructured":"Wendling D, Racadot E, Wijdenes J, Sibilia J, Flipo RM, Cantagrel A, Miossec P, Eschard JP, Macro M, Bertin P, Liote F, Debiais F, Juvin R, Le Goff P, Masson C (1998) A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 25:1457\u20131461","journal-title":"J Rheumatol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/1043-4666(91)90026-A","volume":"3","author":"G Horneff","year":"1991","unstructured":"Horneff G, Krause A, Emmrich F, Kalden JR, Burmester GR (1991) Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis. Cytokine 3:266\u2013267","journal-title":"Cytokine"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.4049\/jimmunol.173.7.4715","volume":"173","author":"D Winsor-Hines","year":"2004","unstructured":"Winsor-Hines D, Merrill C, O\u2019Mahony M, Rao PE, Cobbold SP, Waldmann H, Ringler DJ, Ponath PD (2004) Induction of immunological tolerance\/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol 173:4715\u20134723","journal-title":"J Immunol"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","volume":"200","author":"MR Ehrenstein","year":"2004","unstructured":"Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200:277\u2013285","journal-title":"J Exp Med"},{"key":"13_CR17","first-page":"220","volume":"29","author":"U Mason","year":"2002","unstructured":"Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J (2002) CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 29:220\u2013229","journal-title":"J Rheumatol"},{"key":"13_CR18","first-page":"221","volume":"25","author":"LW Moreland","year":"1998","unstructured":"Moreland LW, Haverty TP, Wacholtz MC, Knowles RW, Bucy RP, Heck LW Jr, Koopman WJ (1998) Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis. J Rheumatol 25:221\u2013228","journal-title":"J Rheumatol"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/art.1780390107","volume":"39","author":"EH Choy","year":"1996","unstructured":"Choy EH, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, Kingsley GH, Panayi GS (1996) Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 39:52\u201356","journal-title":"Arthritis Rheum"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/rheumatology\/37.7.801","volume":"37","author":"EH Choy","year":"1998","unstructured":"Choy EH, Schantz A, Pitzalis C, Kingsley GH, Panayi GS (1998) The pharmacokinetics and human anti-mouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody. Br J Rheumatol 37:801\u2013802","journal-title":"Br J Rheumatol"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/rheumatology\/41.10.1142","volume":"41","author":"EH Choy","year":"2002","unstructured":"Choy EH, Panayi GS, Emery P, Madden S, Breedveld FC, Kraan MC, Kalden JR, Rascu A, Brown JC, Rapson N, Johnston JM (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 41:1142\u20131148","journal-title":"Rheumatology (Oxford)"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/ard.58.6.342","volume":"58","author":"DJ Veale","year":"1999","unstructured":"Veale DJ, Reece RJ, Parsons W, Radjenovic A, O\u2019Connor PJ, Orgles CS, Berry E, Ridgway JP, Mason U, Boylston AW, Gibbon W, Emery P (1999) Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis 58:342\u2013349","journal-title":"Ann Rheum Dis"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004\u20132013","journal-title":"N Engl J Med"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248\u2013255","journal-title":"N Engl J Med"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.139.11.1433","volume":"139","author":"L Skov","year":"2003","unstructured":"Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, Solvsten H, Ibsen HH, Knudsen L, Jensen P, Petersen JH, Menne T, Baadsgaard O (2003) HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 139:1433\u20131439","journal-title":"Arch Dermatol"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/art.20472","volume":"50","author":"Y Hayashi","year":"2004","unstructured":"Hayashi Y, Ishimaru N, Arakaki R, Tsukumo S, Fukui H, Kishihara K, Shiota H, Yasutomo K (2004) Effective treatment of a mouse model of Sjogren\u2019s syndrome with eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum 50:2903\u20132910","journal-title":"Arthritis Rheum"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11882-005-0077-x","volume":"5","author":"M Samarkos","year":"2005","unstructured":"Samarkos M, Moutsopoulos HM (2005) Recent advances in the management of ocular complications of Sjogren\u2019s syndrome. Curr Allergy Asthma Rep 5:327\u2013332","journal-title":"Curr Allergy Asthma Rep"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0896-8411(03)00116-1","volume":"21","author":"E Liu","year":"2003","unstructured":"Liu E, Moriyama H, Paronen J, Abiru N, Miao D, Yu L, Taylor RM, Eisenbarth GS (2003) Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J Autoimmun 21:213\u2013219","journal-title":"J Autoimmun"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.TP.0000118410.61419.59","volume":"77","author":"L Makhlouf","year":"2004","unstructured":"Makhlouf L, Grey ST, Dong V, Csizmadia E, Arvelo MB, Auchincloss H Jr, Ferran C, Sayegh MH (2004) Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 77:990\u2013997","journal-title":"Transplantation"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"12703","DOI":"10.1073\/pnas.96.22.12703","volume":"96","author":"C Kurts","year":"1999","unstructured":"Kurts C, Sutherland RM, Davey G, Li M, Lew AM, Blanas E, Carbone FR, Miller JF, Heath WR (1999) CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 96:12703\u201312707","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10446670310001626508","volume":"10","author":"H Groen","year":"2003","unstructured":"Groen H, Klatter F, Pater J, Nieuwenhuis P, Rozing J (2003) Temporary, but essential requirement of CD8+ T cells early in the pathogenesis of diabetes in BB rats as revealed by thymectomy and CD8 depletion. Clin Dev Immunol 10:141\u2013151","journal-title":"Clin Dev Immunol"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1073\/pnas.1432871100","volume":"100","author":"H Jiang","year":"2003","unstructured":"Jiang H, Curran S, Ruiz-Vazquez E, Liang B, Winchester R, Chess L (2003) Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 100:8378\u20138383","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.4049\/jimmunol.170.5.2508","volume":"170","author":"AC Field","year":"2003","unstructured":"Field AC, Caccavelli L, Bloch MF, Bellon B (2003) Regulatory CD8+ T cells control neonatal tolerance to a Th2-mediated autoimmunity. J Immunol 170:2508\u20132515","journal-title":"J Immunol"},{"key":"13_CR34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1749-6632.2003.tb06042.x","volume":"987","author":"CM Weyand","year":"2003","unstructured":"Weyand CM, Goronzy JJ (2003) Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 987:140\u2013149","journal-title":"Ann N Y Acad Sci"},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1084\/jem.20011565","volume":"195","author":"YM Kang","year":"2002","unstructured":"Kang YM, Zhang X, Wagner UG, Yang H, Beckenbaugh RD, Kurtin PJ, Goronzy JJ, Weyand CM (2002) CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 195:1325\u20131336","journal-title":"J Exp Med"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1000","volume":"3","author":"L Chatenoud","year":"2003","unstructured":"Chatenoud L (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3:123\u2013132","journal-title":"Nat Rev Immunol"},{"key":"13_CR37","first-page":"14","volume":"73","author":"BL Kotzin","year":"2005","unstructured":"Kotzin BL (2005) The role of B cells in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 73:14\u201318","journal-title":"J Rheumatol Suppl"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","volume":"416","author":"EA Leadbetter","year":"2002","unstructured":"Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603\u2013607","journal-title":"Nature"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/ar1184","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, van Venrooij WJ (2004) Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 6:107\u2013111","journal-title":"Arthritis Res Ther"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/art.11229","volume":"48","author":"ER Vossenaar","year":"2003","unstructured":"Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T, van den Berg WB, van Venrooij WJ, Joosten LA (2003) Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 48:2489\u20132500","journal-title":"Arthritis Rheum"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ng1206","volume":"34","author":"A Suzuki","year":"2003","unstructured":"Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395\u2013402","journal-title":"Nat Genet"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1126\/science.1073176","volume":"297","author":"DM Lee","year":"2002","unstructured":"Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB (2002) Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297:1689\u20131692","journal-title":"Science"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/ar70","volume":"2","author":"DE Woolley","year":"2000","unstructured":"Woolley DE, Tetlow LC (2000) Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2:65\u201374","journal-title":"Arthritis Res"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1146\/annurev.iy.08.040190.004013","volume":"8","author":"A Lanzavecchia","year":"1990","unstructured":"Lanzavecchia A (1990) Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 8:773\u2013793","journal-title":"Annu Rev Immunol"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1084\/jem.177.1.109","volume":"177","author":"H Tighe","year":"1993","unstructured":"Tighe H, Chen PP, Tucker R, Kipps TJ, Roudier J, Jirik FR, Carson DA (1993) Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med 177:109\u2013118","journal-title":"J Exp Med"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4049\/jimmunol.167.2.1072","volume":"167","author":"S Takemura","year":"2001","unstructured":"Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O\u2019Fallon WM, Goronzy JJ, Weyand CM (2001) Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167:1072\u20131080","journal-title":"J Immunol"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","volume":"167","author":"S Takemura","year":"2001","unstructured":"Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710\u20134718","journal-title":"J Immunol"},{"key":"13_CR48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.173.2.487","volume":"173","author":"E Roosnek","year":"1991","unstructured":"Roosnek E, Lanzavecchia A (1991) Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 173:487\u2013489","journal-title":"J Exp Med"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.4049\/jimmunol.165.3.1626","volume":"165","author":"IR Rifkin","year":"2000","unstructured":"Rifkin IR, Leadbetter EA, Beaudette BC, Kiani C, Monestier M, Shlomchik MJ, Marshak-Rothstein A (2000) Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol 165:1626\u20131633","journal-title":"J Immunol"},{"issue":"Suppl 3","key":"13_CR50","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1186\/ar1738","volume":"7","author":"E Keystone","year":"2005","unstructured":"Keystone E (2005) B cell targeted therapies. Arthritis Res Ther 7(Suppl 3):S13\u2013S18","journal-title":"Arthritis Res Ther"},{"key":"13_CR51","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253\u20133265","journal-title":"Arthritis Rheum"},{"key":"13_CR52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","volume":"48","author":"DT Boumpas","year":"2003","unstructured":"Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48:719\u2013727","journal-title":"Arthritis Rheum"},{"key":"13_CR53","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"P Woo","year":"2005","unstructured":"Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7:R1281\u2013R1288","journal-title":"Arthritis Res Ther"},{"key":"13_CR54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205\u2013211","journal-title":"Rheumatology (Oxford)"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883\u2013888","journal-title":"Ann Rheum Dis"},{"key":"13_CR56","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","volume":"46","author":"S Vita De","year":"2002","unstructured":"De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029\u20132033","journal-title":"Arthritis Rheum"},{"key":"13_CR57","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"13_CR58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bmt.1704570","volume":"34","author":"J Moore","year":"2004","unstructured":"Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S (2004) A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 34:241\u2013247","journal-title":"Bone Marrow Transplant"},{"key":"13_CR59","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913\u2013920","journal-title":"Ann Rheum Dis"},{"key":"13_CR60","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","volume":"64","author":"A Bhatia","year":"2005","unstructured":"Bhatia A, Ell PJ, Edwards JC (2005) Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64:1099\u20131100","journal-title":"Ann Rheum Dis"},{"key":"13_CR61","first-page":"877","volume":"23","author":"G Cervetti","year":"2005","unstructured":"Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M (2005) High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol 23:877\u2013880","journal-title":"Clin Exp Rheumatol"},{"key":"13_CR62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1568008043339947","volume":"4","author":"S Monaco","year":"2004","unstructured":"Monaco S, Turri E, Zanusso G, Maistrello B (2004) Treatment of inflammatory and paraproteinemic neuropathies. Curr Drug Targets Immune Endocr Metabol Disord 4:141\u2013148","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"13_CR63","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827\u20133834","journal-title":"Blood"},{"key":"13_CR64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-2005-925469","volume":"31","author":"C Porta","year":"2005","unstructured":"Porta C, Caporali R, Montecucco C (2005) Autoimmunity in thrombotic thrombocytopenic purpura. Semin Thromb Hemost 31:633\u2013640","journal-title":"Semin Thromb Hemost"},{"key":"13_CR65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0300-9475.2004.01441.x","volume":"60","author":"P Szodoray","year":"2004","unstructured":"Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M (2004) Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 60:209\u2013218","journal-title":"Scand J Immunol"},{"key":"13_CR66","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146\u20132154","journal-title":"Arthritis Rheum"},{"issue":"Suppl 4","key":"13_CR67","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/ar1008","volume":"5","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth JD (2003) Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 5(Suppl 4):S12\u2013S16","journal-title":"Arthritis Res Ther"},{"key":"13_CR68","first-page":"207","volume":"22","author":"GW Cannon","year":"1995","unstructured":"Cannon GW, Marble DA, Griffiths MM, Cole BC, McCall S, Schulman SF, Strand V (1995) Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate. J Rheumatol 22:207\u2013213","journal-title":"J Rheumatol"},{"key":"13_CR69","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.1780390705","volume":"39","author":"NJ Olsen","year":"1996","unstructured":"Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, Nelson B, Lorenz T, Strand V (1996) A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum 39:1102\u20131108","journal-title":"Arthritis Rheum"},{"key":"13_CR70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.1780380215","volume":"38","author":"EM Ruderman","year":"1995","unstructured":"Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM (1995) Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 38:254\u2013258","journal-title":"Arthritis Rheum"}],"container-title":["Springer Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-006-0013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-006-0013-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-006-0013-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T06:59:06Z","timestamp":1683442746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-006-0013-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,28]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s00281-006-0013-8","relation":{},"ISSN":["0344-4325","1432-2196"],"issn-type":[{"value":"0344-4325","type":"print"},{"value":"1432-2196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,28]]}}}